PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression

Nature Medicine

Volumn 22, Issue 11, 2016, Pages 1321-1329

  Horiuchi, Dai ^a,b,c   Camarda, Roman ^a   Zhou, Alicia Y ^a,g   Yau, Christina ^d,e   Momcilovic, Olga ^a   Balakrishnan, Sanjeev ^a,h   Corella, Alexandra N ^a,i,j   Eyob, Henok ^a,k   Kessenbrock, Kai ^d,l   Lawson, Devon A ^d,l   Marsh, Lindsey A ^c   Anderton, Brittany N ^a,m   Rohrberg, Julia ^a   Kunder, Ratika ^c   Bazarov, Alexey V ^f,n   Yaswen, Paul ^f   McManus, Michael T ^d   Rugo, Hope S ^d   Werb, Zena ^b,d   Goga, Andrei ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^f LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^g Dovetail Genomics ^*  (United States)

^h Dovetail Genomics   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j USA   (United States)

^k BOSTON CONSULTING GROUP   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ Cypre Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 1 INHIBITOR; PROTEIN P27 INHIBITOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; CDKN1B PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTROGEN RECEPTOR; MYC PROTEIN, HUMAN; MYC PROTEIN, MOUSE; PIM1 PROTEIN, HUMAN; PIM1 PROTEIN, MOUSE; PROGESTERONE RECEPTOR; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FLUORESCENCE MICROSCOPY; GENETICS; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; PAGET NIPPLE DISEASE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; TUNEL ASSAY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IN SITU NICK-END LABELING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-PIM-1; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84992376478     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4213     Document Type: Article

References (51)

1. Foulkes, W.D., Smith, I.E. & Reis-Filho, J.S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938-1948 (2010).
2. Horiuchi, D. et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J. Exp. Med. 209, 679-696 (2012).
3. Prochownik, E.V. & Vogt, P.K. Therapeutic targeting of Myc. Genes Cancer 1, 650-659 (2010).
4. Kaelin, W.G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698 (2005).
5. Mukhopadhyay, R. et al. Promotion of variant human mammary epithelial cell outgrowth by ionizing radiation: an agent-based model supported by in vitro studies. Breast Cancer Res. 12, R11 (2010).
6. Littlewood, T.D., Hancock, D.C., Danielian, P.S., Parker, M.G. & Evan, G.I. A modifed estrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23, 1686-1690 (1995).
7. Kessler, J.D. et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335, 348-353 (2012).
8. Sato, M. et al. MYC is a critical target of FBXW7. Oncotarget 6, 3292-3305 (2015).
9. Bazarov, A.V. et al. Telomerase activation by c-MYC in human mammary epithelial cells requires additional genomic changes. Cell Cycle 8, 3373-3378 (2009).
10. Nawijn, M.C., Alendar, A. & Berns, A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer 11, 23-34 (2011).
11. Mikkers, H. et al. Mice defcient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol. Cell. Biol. 24, 6104-6115 (2004).
12. van Lohuizen, M. et al. Predisposition to lymphomagenesis in Pim1 transgenic mice: cooperation with c-Myc and N-Myc in murine leukemia virus-induced tumors. Cell 56, 673-682 (1989).
13. Wang, J. et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29, 2477-2487 (2010).
14. Wang, J. et al. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene 31, 1794-1803 (2012).
15. Kirschner, A.N. et al. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J. Natl. Cancer Inst. 107, dju407 (2014).
16. Xie, Y. et al. The 44-kDa Pim-1 kinase directly interacts with tyrosine kinase ETK (BMX) and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 25, 70-78 (2006).
17. Malinen, M. et al. Proto-oncogene PIM1 is a novel estrogen receptor target associating with high-grade breast tumors. Mol. Cell. Endocrinol. 365, 270-276 (2013).
18. Chen, L.S., Redkar, S., Bearss, D., Wierda, W.G. & Gandhi, V. Pim kinase inhibitor SGI-1776 induces apoptosis in chronic lymphocytic leukemia cells. Blood 114, 4150-4157 (2009).
19. DeRose, Y.S. et al. Tumor grafts derived from women with breast cancer authentically refect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514-1520 (2011).
20. Lu, J. et al. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood 122, 1610-1620 (2013).
21. Burger, M.T. et al. Identifcation of N-(4-((1R, 3S, 5S)-3-amino-5-methylcyclohexyl) pyridin-3-yl)-6-(2, 6-difuorophenyl)-5-fuoropicolinamide (PIM447), a potent and selective proviral insertion site of Moloney murine leukemia (PIM) 1, 2 and 3 kinase inhibitor in clinical trials for hematological malignancies. J. Med. Chem. 58, 8373-8386 (2015).
22. D'Cruz, C.M. et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7, 235-239 (2001).
23. Zhang, Y., Wang, Z., Li, X. & Magnuson, N.S. Pim-kinase-dependent inhibition of c-Myc degradation. Oncogene 27, 4809-4819 (2008).
24. Sears, R.C. The life cycle of c-Myc: from synthesis to degradation. Cell Cycle 3, 1133-1137 (2004).
25. Zhang, Y., Wang, Z. & Magnuson, N.S. Pim-1-kinase-dependent phosphorylation of p21Cip1 (WAF1) regulates its stability and cellular localization in H1299 cells. Mol. Cancer Res. 5, 909-922 (2007).
26. Morishita, D., Katayama, R., Sekimizu, K., Tsuruo, T. & Fujita, N. Pim kinases promote cell cycle progression by phosphorylating and downregulating p27Kip1 at the transcriptional and post-transcriptional levels. Cancer Res. 68, 5076-5085 (2008).
27. Bachmann, M. et al. The oncogenic serine-threonine kinase Pim-1 directly phosphorylates and activates the G2/M-specifc phosphatase Cdc25C. Int. J. Biochem. Cell Biol. 38, 430-443 (2006).
28. Mochizuki, T. et al. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J. Biol. Chem. 274, 18659-18666 (1999).
29. Yan, B. et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J. Biol. Chem. 278, 45358-45367 (2003).
30. Fox, C.J. et al. The serine-threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 17, 1841-1854 (2003).
31. Wang, X. et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res. 71, 925-936 (2011).
32. O'Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V. & Mendell, J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839-843 (2005).
33. Brasó-Maristany, F. et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat. Med. 22, 1303-1313 (2016).
34. Mohanty, A.R. et al. Successive phosphorylation of p27KIP1 protein at Ser10 and C terminus crucially controls its potency to inactivate Cdk2. J. Biol. Chem. 287, 21757-21764 (2012).
35. Fujita, N., Sato, S., Katayama, K. & Tsuruo, T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 277, 28706-28713 (2002).
36. Czabotar, P.E., Lessene, G., Strasser, A. & Adams, J.M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49-63 (2014).
37. Chu, I.M., Hengst, L. & Slingerland, J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8, 253-267 (2008).
38. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 490, 61-70 (2012).
39. Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716 (2003).
40. INK4a-mediated suppression of telomerase in normal and malignant human breast cells. Aging Cell 9, 736-746 (2010).
41. Yau, C. et al. A multigene predictor of metastatic outcome in early-stage hormone-receptor-negative and triple-negative breast cancer. Breast Cancer Res. 12, R85 (2010).
42. Esserman, L.J. et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res. Treat. 132, 1049-1062 (2012).
43. Hatzis, C. et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. J. Am. Med. Assoc. 305, 1873-1881 (2011).
44. Davis, S. & Meltzer, P.S. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 23, 1846-1847 (2007).
45. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).
46. Langfelder, P. & Horvath, S. Fast R functions for robust correlations and hierarchical clustering. J. Stat. Softw. 46, i11 (2012).
47. Wickham, H. ggplot2 (Springer Science and Business Media, 2009).
48. Therneau, T.M. Modeling Survival Data: Extending the Cox Model (Springer Science and Business Media, 2000).
49. Neve, R.M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
50. Chen, L.S., Redkar, S., Taverna, P., Cortes, J.E. & Gandhi, V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 118, 693-702 (2011).
51. Garcia, P.D. et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin. Cancer Res. 20, 1834-1845 (2014).